Regencell Bioscience (RGC) | Stock Overview & Key Data
Regencell Bioscience Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $950.00 on May 30, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.00B Large-cap | -20.10% | -40.20% | -24.65% | -0.98% | -16.80% | 20.24% | 2,888.89% | 6,625.00% | 6,625.00% | 6,625.00% | 6,625.00% | |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
United Therapeutics
UTHR
|
25.11B Large-cap | 0.90% | -3.34% | 2.86% | 9.85% | 10.64% | 92.68% | 137.11% | 205.88% | 434.68% | 903.79% | 2,026.01% |
|
Viatris
VTRS
|
16.99B Large-cap | 2.45% | -0.97% | 20.80% | 39.97% | 30.98% | 84.75% | 60.16% | 15.57% | -63.39% | -26.00% | -21.07% |
|
Intra-Cellular
ITCI
|
14.05B Large-cap | N/A | N/A | N/A | N/A | N/A | 92.68% | 104.13% | 700.67% | 449.92% | 632.61% | 632.61% |
Ownership & Short Interest
Calculate Your Regencell Bioscience Investment Returns
Long-Term Investment Performance Analysis
Regencell Bioscience stock price in Jul 2021 was $0.28, A $1,000.00 lump sum investment in Regencell Bioscience made 4 years ago would be worth approximately $61,035.71 today, representing a exceptional return of 6,003.57%. This translates to an annualized return (CAGR) of 130.42%.
4 Years 11 Months Investment Scenario (Jul 2021 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is RGC's 52-week high and low?
- In the last 52 weeks, Regencell Bioscience reached a high of $83.60 (on June 16, 2025) and a low of $9.39 (on July 2, 2025).
- What is the market cap and P/E ratio for RGC?
- Curious about Regencell Bioscience's size and valuation? Its market capitalization stands at 14.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is -3,258.62, and the forward P/E (looking ahead) is N/A.
- Does RGC pay dividends? If so, what's the yield?
- As for dividends, Regencell Bioscience isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Regencell Bioscience's main competitors or similar companies to consider before investing?
When looking at Regencell Bioscience, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% United Therapeutics
UTHR25.11B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 137.11% Viatris
VTRS16.99B Healthcare Drug Manufacturers - Specialty & Generic 84.75% 60.16% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Regencell Bioscience Holdings Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Regencell Bioscience's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -54.81%, the Debt to Equity ratio from the most recent quarter is 11.20, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RGC?
- Looking at Regencell Bioscience's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of RGC stock is held by insiders and institutions?
- Wondering who owns Regencell Bioscience stock? Company insiders (like executives and directors) hold about 88.56% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.12%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.